Merck stock heads into Monday with Keytruda, Welireg cancer data and FDA review dates on deck
Merck shares rose 3.8% to $123.82 Friday, trading on heavy volume. The company reported Phase 3 trial results showing Keytruda-based combinations improved survival in ovarian and kidney cancers. The FDA set June 19 and Oct. 4, 2026, target dates for reviews of Keytruda and Welireg combinations in kidney cancer. Keytruda accounted for nearly half of Merck’s 2025 revenue, with major patents expiring in 2028.
